Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Regardless of adherence to weekly Wegovy (semaglutide) injections, adults with obesity who received a higher dose of the medication lost an average ... estimated weight loss would be 20.7% for ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks.

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks.